Search Results
Jun 01, 2026, 07:00 ET Actinium Pharmaceuticals Presents New Radiochemistry Data at SNMMI 2026 Demonstrating That CAR Optimization Improves Tumor Targeting and Pharmacokinetics of Actinium-225 Radioconjugates
with the National Cancer Institute (NCI); and (3) targeted conditioning agents including Iomab-B for bone marrow transplant and Iomab-ACT for cell and gene therapy conditioning. ATNM-400 targets a novel antigen distinct from PSMA and has demonstrated preclinical activity across metastatic castration-resistant
More news about: Actinium Pharmaceuticals, Inc.
Jun 01, 2026, 06:01 ET A combined therapeutic strategy aims to improve disease control in advanced hormone‑sensitive prostate cancer
(SERD) elacestrant combined with everolimus versus elacestrant monotherapy. The study includes patients with ER+/HER2‑ tumors who developed an ESR1 gene mutation after progression on prior endocrine therapy and CDK4/6 inhibitors. The trial is being implemented in more than 100 hospitals across nine countries,
More news about: MEDSIR
May 31, 2026, 20:00 ET 2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer
certain patients, treatment options remain extremely limited for patients with NSCLC who do not respond to immunotherapy and lack actionable driver gene mutations, making long-term survival difficult to achieve.The proof-of-concept (PoC) data presented at this year's ASCO meeting are highly encouraging.
More news about: Innovent Biologics
May 31, 2026, 20:00 ET 2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC
Guangdong Provincial People's Hospital stated: "At present, first-line standard treatment for advanced non-small cell lung cancer without driver gene alterations is mainly PD-1/PD-L1 antibodies plus chemotherapy. With the advent of a new generation of immunotherapies, first-line NSCLC research has
More news about: Innovent Biologics
May 31, 2026, 08:01 ET Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer
of:Adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by an FDA-approved testIMPORTANT SAFETY INFORMATION FOR RETEVMO (selpercatinib)Hepatotoxicity:
More news about: Eli Lilly and Company
May 30, 2026, 20:09 ET Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO 2026
positive (EGFRm) NSCLC.Non-small cell lung cancer is the leading cause of cancer death in the world. Epidermal growth factor receptor (EGFR) gene is one of the most common driver genes for NSCLC. Multiple agents can be used to treat patients with EGFR mutated NSCLC who develop resistance to EGFR
More news about: Dizal Pharmaceutical
May 30, 2026, 09:07 ET Menarini Group apresenta novos dados do estudo ELEVATE de Fase 1b/2 sobre o elacestranto em associação com o capivasertibe em pacientes com câncer de mama metastático (CMm) ER+, HER2- no Congresso Anual de 2026 da American Society of Clinical Oncology (ASCO)
comparando elacestranto + everolimo versus elacestrant + placebo em pacientes com câncer de mama avançado ER+/HER2- com tumores portadores de mutação no gene ESR1 que apresentaram progressão durante a terapia endócrina + inibidor de CDK4/6*#Número do resumo: TPS1154Data e hora
More news about: Menarini Industrie Farmaceutiche Riunite
May 30, 2026, 06:36 ET Chandigarh University Research Scientist Receives Startup Research Grant of Rs 24 Lakhs
traits in early generations without waiting for the plants to mature and be subjected to stress conditions. Analysis of DNA methylation together with gene expression highlights the genes and metabolic pathways most sensitive to the combined stress of increased CO2 and temperature during grain filling.
More news about: Chandigarh University
May 29, 2026, 17:48 ET Researchers From NYU Langone Health's Perlmutter Cancer Center Present Latest Findings at 2026 ASCO Annual Meeting
known for its biological complexity and variable response to treatment. Investigators created a prognostic tool that outperformed several commonly used gene expression signatures in identifying higher-risk disease.The study used data from patients in a cohort tracked by Stand Up to Cancer and applied
More news about: NYU Langone Health System
May 29, 2026, 17:31 ET Actinium Pharmaceuticals Receives Two Patent Allowances Spanning Its Actimab-A and Iomab-ACT Programs
will have a patent term running into January 2039.Iomab-ACT for Gene-Edited Cell-Based TherapiesThe allowed application covers Actinium's targeted CD45 conditioning approach used to prepare patients for gene-edited cell-based therapies. Iomab-ACT is designed as a targeted conditioning
More news about: Actinium Pharmaceuticals, Inc.
May 29, 2026, 17:30 ET Actinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE American Listing Standards Notice
with the National Cancer Institute (NCI); and (3) targeted conditioning agents including Iomab-B for bone marrow transplant and Iomab-ACT for cell and gene therapy conditioning. ATNM-400 targets a novel antigen distinct from PSMA and has demonstrated preclinical activity across metastatic castration-resistant
More news about: Actinium Pharmaceuticals, Inc.
May 29, 2026, 11:40 ET Le Groupe Menarini présente de nouvelles données de l'étude ELEVATE sur l'association de l'élacestrant et du capivasertib
résistance observés dans le cancer du sein métastatique ER+/HER2- et améliorer les résultats pour les patients, quel que soit le statut mutationnel du gène ESR1. L'étude est composée de six schémas thérapeutiques évaluant l'élacestrant en association avec des inhibiteurs de CDK4/6 (palbociclib, abémaciclib
More news about: Menarini Industrie Farmaceutiche Riunite
May 29, 2026, 04:49 ET Decoding Jingdezhen Ceramics with Tech
details are being transformed into data that will never decay.Behind the quiet galleries lies a powerful digital infrastructure: the Ceramic Gene Bank. It is the world's first systematic digital platform built around the concept of ceramic genes. Its construction began in 2022, drawing on nearly
More news about: Science and Technology Daily
May 28, 2026, 12:30 ET Illumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology research
oncoReveal® Nexus 21 Gene Panel offers rapid solid tumor and hematological malignancy sequencing for multiple cancer types including NSCLC, endometrial, AML, B-Cell Lymphoma and MPN.The oncoReveal® Lymphoid Panel is an 84 gene DNA panel spanning high-value
More news about: Illumina, Inc.
May 28, 2026, 11:45 ET Sino Biological's Cell-Free Protein Synthesis Supports Tencent AI for Life Sciences Lab's Protein Design Study Published in Nature Communications
May 28, 2026 /PRNewswire/ -- Sino Biological, Inc. (Shenzhen Stock Exchange: 301047.SZ) has announced that its gene synthesis and cell-free protein expression workflow was used in a
More news about: Sino Biological, Inc.
May 28, 2026, 09:15 ET Anti-Aging Cell Therapy Reaches Major GMP Milestone as Wave of Clinical Advancements Gain Momentum
Influential Companies list — are advancing one of the more visible gene-editing-enabled accelerated regulatory pathways in the sector. The BEAM-302 expansion represents the type of regulatory derisking that the broader cell and gene therapy complex has needed at the clinical-to-commercial transition.
More news about: USA News Group
May 28, 2026, 09:00 ET China-US Dual Filing Success: Porton Advanced's End-to-End Bacterial Vector CDMO Solution Accelerates NMPA Approval of Salvectors' Innovative Oncolytic Bacteria Therapy
CRANBURY, N.J. and SUZHOU, China, May 28, 2026 /PRNewswire/ -- Porton Advanced, a leading cell and gene therapy CDMO, recently announced its client Salvectors has received Investigational New Drug (IND) clearance for their proprietary and innovative oncolytic
More news about: Porton Advanced
May 28, 2026, 08:30 ET Prevent Advanced Therapy Program Delays with Early Supply Chain Strategy, Upcoming Webinar Hosted by Xtalks
regulatory readiness, improve scalability and reduce downstream risk.Join Lorraine Hicks, Supply Chain & Clinical Logistics Expert / Cell & Gene Therapy Specialist; Dominic Clarke, PhD, Associate Chief Scientific Officer, Cryoport, Inc. / Vice President - Technical Operations, Integricell®, Cryoport
More news about: Xtalks
May 28, 2026, 07:08 ET China-US Dual Filing Success: Porton Advanced's End-to-End Bacterial Vector CDMO Solution Accelerates NMPA Approval of Salvectors' Innovative Oncolytic Bacteria Therapy
SUZHOU, China and CRANBURY, N.J., May 28, 2026 /PRNewswire/ -- Porton Advanced, a leading cell and gene therapy CDMO, recently announced its client Salvectors has received Investigational New Drug (IND) clearance for their proprietary and innovative oncolytic
More news about: Porton Advanced
May 28, 2026, 07:00 ET Labcorp Launches Expanded DPYD Test to Identify Cancer Patients at Risk for Severe Chemotherapy Side Effects
1,300 deaths in the United States each year from 5-FU toxicity.The DPYD gene encodes the enzyme DPD, which metabolizes more than
More news about: Labcorp
May 28, 2026, 05:15 ET Sino Biological's Cell-Free Protein Synthesis Supports Tencent AI for Life Sciences Lab's Protein Design Study Published in Nature Communications
May 28, 2026 /PRNewswire/ -- Sino Biological, Inc. (Shenzhen Stock Exchange: 301047.SZ) has announced that its gene synthesis and cell-free protein expression workflow was used in a
More news about: Sino Biological, Inc.
May 27, 2026, 18:00 ET FDA Breakthrough Device Designation Marks Major Milestone for Gene Solutions' SPOT-MAS 10 Multi-Cancer Screening Test
provides Gene Solutions with a prioritized channel of engagement with the FDA as the company advances its U.S. development and validation plans. Gene Solutions is targeting U.S. launch readiness in late 2026, supported by its ongoing U.S. laboratory and validation strategy.Looking ahead, Gene Solutions
More news about: GENE SOLUTIONS SGP PTE. LTD.
May 27, 2026, 17:00 ET Phase 3 HERIZON-GEA-01 Results Published in The New England Journal of Medicine Show Durable and Consistent Survival Benefit with Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA
metastatic GEA. The FDA granted two Breakthrough Therapy designations for zanidatamab's development: one as a single agent for previously treated HER2 gene-amplified BTC, and one in combination with fluoropyrimidine- and platinum-containing chemotherapy, with or without tislelizumab for first-line HER2+
More news about: Jazz Pharmaceuticals plc
May 27, 2026, 16:15 ET CPC Biotech Collaborates with Multiply Labs to Advance Cell Therapy Automation
accelerating patient access to advanced therapies," said Troy Ostreng, Senior Product Manager for CPC Biotech's biopharmaceutical and cell therapy and gene therapy (CGT) businesses. "To meet the growing need for faster, more efficient, high-quality cell therapy manufacturing, we're developing a first-ever
More news about: Dover
May 27, 2026, 08:31 ET Wet AMD Market Set for Robust Growth Through 2036, Driven by Advancements in Anti-VEGF Therapies | DelveInsight
AI-based diagnostic tools have significantly enhanced early detection and disease monitoring.Emerging Gene and Stem Cell Therapies Redefining Wet AMD Management: Emerging gene and stem cell therapies (e.g., RGX-314, Ixo-vec) offer durable, potentially one-time treatments for wet AMD, reducing
More news about: DelveInsight Business Research, LLP